logo image
search icon
Biologics CDMO Market

Biologics CDMO Market Size, Share & Trends Analysis Report By Cell Type (Mammalian, Non-mammalian), By Product Type (Biologics (Monoclonal Antibodies, Recombinant Proteins, Antisense and Molecular Therapy, Vaccines, Other Biologics, Biosimilars), By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2233 | Published : 2023-11-28 | Pages: 180 | Format: PDF/EXCEL

Biologics CDMO Market Size is valued at USD 14.06 Bn in 2022 and is predicted to reach USD 35.09 Bn by the year 2031 at a 10.79% CAGR during the forecast period for 2023-2031.

Biologics CDMO Market

Biologics Contract Development and Manufacturing Organisations (CDMOs) are essential in developing and manufacturing biopharmaceuticals, also known as biologics. These organisations provide specialised services to biopharmaceutical businesses, assisting them from the early stages of drug discovery to commercial manufacturing. Several variables influence the Biologics Contract Development and Manufacturing Organisation (CDMO) market's growth and development. These factors represent rising biologics demand, advances in biopharmaceutical technology, and the changing landscape of the pharmaceutical and biotechnology industry. The rising prevalence of complicated disorders, combined with the efficacy of biologics in treating various ailments, has increased the demand for biopharmaceuticals.

However, the COVID-19 pandemic has already had an impact on the pharmaceutical and biopharmaceutical industries, especially the Biologics CDMO (Contract Development and Manufacturing Organisation) market. The epidemic disrupted global supply chains, affecting raw materials and essential components used in biologics development. CDMOs encountered logistical, transportation, and procurement problems that hampered their ability to sustain flawless operations.

Competitive Landscape

Some Major Key Players In The Biologics CDMO Market:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing
  • JRS Pharma
  • Fujifilm Diosynth Biotechnologies USA Inc.
  • Wuxi Biologics
  • Others

Market Segmentation:

The Biologics CDMO Market is segmented on the basis of cell type and product type. According to cell type, the market is segmented as Mammalian and Non-mammalian. The product type segment includes Biologics and Biosimilars. By biologics, the market is segmented into monoclonal antibodies, recombinant proteins, antioxidant and molecular therapy, vaccines, and other biologics.

Based On Cell Type, The Mammalian Segment Is A Major Contributor To The Biologics CDMO Market. 

The Mammalian category is expected to hold a major share of the global Biologics CDMO Market in 2022. Various variables influence the Biologics Contract Development and Manufacturing Organisation (CDMO) market for mammalian cell-based processes, reflecting the increasing demand for biologics manufactured utilising mammalian cell cultures. Mammalian cells are frequently utilised to produce complicated biopharmaceuticals (monoclonal antibodies and recombinant proteins).

The growing pipeline of biopharmaceuticals, particularly those involving large and complicated compounds, needs synthesis in mammalian cell cultures. CDMOs that specialise in mammalian cell-based processes are well-positioned to help with the development and production of these sophisticated therapies.

The Monoclonal Antibodies Segment Witness Growth At A Rapid Rate.

The monoclonal antibodies segment is likely to grow rapidly in the global Biologics CDMO Market. Several factors influence the Biologics Contract Development and Manufacturing Organisation (CDMO) market, focusing on monoclonal antibodies (mAbs), reflecting the increasing need for mAb-based therapeutics. Monoclonal antibodies are commonly utilised to treat cancer, autoimmune disorders, and infectious diseases and other similar diseases. The development of several monoclonal antibody platforms, including classic and next-generation formats, broadens therapeutic intervention choices.

In The Region, The North America Biologics CDMO Market Holds A Significant Revenue Share.

The North American Biologics CDMO Market is expected to record the maximum market share in revenue in the near future due to the existence of two major economies, notably the United States and Canada. The United States has one of the world's largest pharmaceutical sectors, accounting for a sizable portion of market sales. The increasing prevalence of chronic diseases, population ageing, and the increased requirement for evidence-based practice are all factors that have contributed to the strong need for clinical trials in the United States.

In recent years, the location of clinical trials has migrated from academic medical centres to community-based practises to worldwide venues in various countries. Moreover, the Asia Pacific biopharmaceutical sector is expanding rapidly, owing to rising healthcare costs, the frequency of chronic diseases, and scientific developments. This expansion presents the potential for Biologics CDMOs to support biologics development and manufacture.

Recent Developments:

  • In April 2023, Lonza entered into a partnership with ABL Bio, a company specializing in the development of bispecific antibodies for the treatment of immuno-oncology and neurological illnesses.     The purpose of the agreement was to facilitate the advancement and production of ABL Bio's novel bispecific antibody product. 
  • In April 2022, ChimeronBio established a manufacturing collaboration with FUJIFILM Diosynth Biotechnologies (FDB) in order to expand its Oncology portfolio to encompass clinics. ChimeronBio chose FUJIFILM Diosynth Biotechnologies as its partner in the transfer and scalability of its medicinal substance manufacturing method.

Biologics CDMO Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 14.06 Bn

Revenue Forecast In 2031

USD 35.09 Bn

Growth Rate CAGR

CAGR of 10.79% from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Cell Type, Product Type

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Boehringer Ingelheim Group, Lonza Group, Samsung Biologics, NOVARTIS AG, Toyobo Co. Limited, Parexel International Corporation, Catalent Inc., Binex Co. Limited, AGC Biologics, AbbVie Contract Manufacturing, JRS Pharma, Fujifilm Diosynth Biotechnologies USA Inc., Wuxi Biologics and Others.

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Biologics CDMO Market Snapshot

Chapter 4. Global Biologics CDMO Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Cell Type Estimates & Trend Analysis

5.1. By Cell Type, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Cell Type:

5.2.1. Residential

5.2.2. Commercial

5.2.3. Industrial

5.2.4. Others

Chapter 6. Market Segmentation 2: By Product Type Estimates & Trend Analysis

6.1. By Product Type & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Product Type:

6.2.1. Biologics

6.2.1.1. Monoclonal Antibodies

6.2.1.2. Recombinant Proteins

6.2.1.3. Antisense and Molecular Therapy

6.2.1.4. Vaccines

6.2.1.5. Other Biologics

6.2.2. Biosimilars

Chapter 7. Biologics CDMO Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Cell Type, 2019-2031

7.1.2. North America Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Product Type, 2019-2031

7.1.3. North America Biologics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

7.2. Europe

7.2.1. Europe Biologics CDMO Market revenue (US$ Million) By Cell Type, 2019-2031

7.2.2. Europe Biologics CDMO Market revenue (US$ Million) By Product Type, 2019-2031

7.2.3. Europe Biologics CDMO Market revenue (US$ Million) by country, 2019-2031

7.3. Asia Pacific

7.3.1. Asia Pacific Biologics CDMO Market revenue (US$ Million) By Cell Type, 2019-2031

7.3.2. Asia Pacific Biologics CDMO Market revenue (US$ Million) By Product Type, 2019-2031

7.3.3. Asia Pacific Biologics CDMO Market revenue (US$ Million) by country, 2019-2031

7.4. Latin America

7.4.1. Latin America Biologics CDMO Market revenue (US$ Million) By Cell Type, (US$ Million) 2019-2031

7.4.2. Latin America Biologics CDMO Market revenue (US$ Million) By Product Type, (US$ Million) 2019-2031

7.4.3. Latin America Biologics CDMO Market revenue (US$ Million) by country, 2019-2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa Biologics CDMO Market revenue (US$ Million) By Cell Type, (US$ Million) 2019-2031

7.5.2. Middle East & Africa Biologics CDMO Market revenue (US$ Million) By Product Type, (US$ Million) 2019-2031

7.5.3. Middle East & Africa Biologics CDMO Market revenue (US$ Million) by country, 2019-2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Boehringer Ingelheim Group

8.2.2. Lonza Group

8.2.3. Samsung Biologics

8.2.4. NOVARTIS AG

8.2.5. Toyobo Co. Limited

8.2.6. Parexel International Corporation

8.2.7. Catalent Inc.

8.2.8. Binex Co. Limited

8.2.9. AGC Biologics

8.2.10. AbbVie Contract Manufacturing

Segmentation of Biologics CDMO Market-

Biologics CDMO Market By Cell Type-

  • Mammalian
  • Non-mammalian

Biologics CDMO Market Seg

Biologics CDMO Market By Product Type-

  • Biologics
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Antisense and Molecular Therapy
    • Vaccines
    • Other Biologics
  • Biosimilars

Biologics CDMO Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Biologics CDMO Market?

Biologics CDMO Market at a 10.79% CAGR during the forecast period for 2023-2031.

JRS Pharma, Fujifilm Diosynth Biotechnologies USA Inc., Wuxi Biologics and Others.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach